US 2005/0089939 A1 · Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology

Abstract

The present invention provides a method of treating Alzheimer's Disease by blocking CD-40 receptor-mediated, Aβ-induced microglial cell activation with an agent. Also provided is a method of determining the therapeutic effectiveness of an agent for Alzheimer's Disease by measuring the inhibition of the interaction between the CD40 receptor and its ligand (CD40L) in the presence of the agent. The present invention further provides a method of testing the efficacy of a therapeutic agent by producing a TgAppSW/CD40L deficient mouse and administering to the mouse the therapeutic agent to be tested and determining the efficacy of the drug in suppressing neurodegeneration of Alzheimer's Disease.

Claims6

Dependent claims

1-9. (canceled)

Dependencies are inferred from the claim text.

Facts

Application

10/842,212Filed 10 May 2004

Priority

1 Jun 1999

Published

28 Apr 2005

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

G01N 33/502
For testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics: for testing non-proliferative effects
G01N 33/5008
Involving human or animal cells: for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
G01N 33/5044
For testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics: involving specific cell types
G01N 33/5058
Involving specific cell types: neurological cells

Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology

Life of this patent

Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology

Life of this patent

Abstract

Claims6